COEP - NASDAQ

Coeptis Therapeutics, Inc.

Coeptis Therapeutics, Inc.

COEPยทNASDAQ

$16.40

+0.0000%
HealthcareBiotechnology

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$57.63M
EPS-2.8100
P/E Ratio-5.84
Earnings Date06/03/2026
Coeptis Therapeutics, Inc.

Coeptis Therapeutics, Inc. Fair Value Envelope

COEP ยท NASDAQ

Our analysis suggests that COEP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.4, this represents a potential HIDDEN relative to our calculated worth for Coeptis Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $16.4

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$16.0M
+ Cash & Equivalents$5.7M
Firm Value-$10.3M
- Debt$268.9K
Equity Value-$10.6M
/ Shares Outstanding3,513,840B
DCF Value-$3
OVERVALUED BY 118%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$6.1M
-$4.3M
-$3.0M
-$2.1M
-$1.5M
-$1.1M
-$753.4K
-$532.0K
-$375.7K
-$265.3K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$6.1M
-$4.3M
-$3.0M
-$2.1M
-$1.5M
-$1.1M
-$753.4K
-$532.0K
-$375.7K
-$265.3K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$5.6M
-$3.7M
-$2.4M
-$1.6M
-$1.0M
-$672.3K
-$439.6K
-$287.4K
-$187.9K
-$122.9K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your COEP research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.